Drug & intervention

orlistat

RxCUI 37925

Clinical trials25
Recruiting0
Related conditions19
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Orlistat

Orlistat, sold under the brand name Xenical among others, is a medication used to treat obesity. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet. Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini. However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug. The effectiveness of orlistat in promoting weight loss is definite but modest. Pooled data from clinical trials suggest that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2–3 kilograms (4–7 lb) more than those not taking the drug over the course of a year. Orlistat also modestly reduces blood pressure and appears to prevent the onset of type 2 diabetes, whether from the weight loss itself or other effects. It reduces the incidence of diabetes type 2 in people who are obese around the same amount that lifestyle changes do. Benefits aside, however, orlistat is noted for its gastrointestinal side effects (sometimes referred to as treatment effects), which can include steatorrhea (oily, loose stools). They decrease with time, however, and are the most frequently reported adverse effects of the drug. In Australia, the United States and the European Union, orlistat is available for sale without a prescription. O...

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

25 shown
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver DiseaseNCT06501326 · 2023-11-01
UNKNOWN
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in AmericaNCT05579249 · 2023-01-19
COMPLETED
Orlistat Reduces Uric Acid in Overweight/Obese Patients With HyperuricemiaNCT05496075 · 2022-08-26
COMPLETED
EMI-EHP Weight Management and Type 2 Diabetes Pragmatic TrialNCT04531176 · 2020-09-01
TERMINATED
Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained InfertilityNCT02432209 · 2015-08-01
COMPLETED
Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep ApneaNCT02069197 · 2014-01-01
UNKNOWN
Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric BandingNCT01597531 · 2012-06-01
TERMINATED
The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese SubjectsNCT01719419 · 2012-03-01
WITHDRAWN
Comparison of MAG and Fish Oil EfficacyNCT01797757 · 2012-01-01
COMPLETED
Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With ObesityNCT01351753 · 2011-03-01
TERMINATED
Assess the Additional Weight Loss Effect of Orlistat Used in Combination With SibutramineNCT01184560 · 2010-02-01
COMPLETED
A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.NCT01035333 · 2009-11-01
COMPLETED
Study of Fat Malabsorption by Lipiblock Versus XenicalNCT01170806 · 2009-10-01
COMPLETED
Orlistat Induced Modulation on the Fatty Acid Composition in Obese FemalesNCT01414465 · 2009-10-01
COMPLETED
Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) PatientsNCT01003483 · 2008-12-01
COMPLETED
Effect of Orlistat in Body CompositionNCT00752726 · 2008-09-01
COMPLETED
The Effect of Liraglutide on Body Weight in Obese Subjects Without DiabetesNCT00422058 · 2007-01-10
COMPLETED
Growth Factor/Insulin-like Growth Factor (GH/IGF)-1 Axis in Obese Subjects in Treatment With OrlistatNCT00991926 · 2006-12-01
COMPLETED
The Effect of Xenical on Weight and Risk FactorsNCT00152360 · 2005-06-01
COMPLETED
Efficacy and Safety of ATL-962 in Obese DiabeticsNCT00156897 · 2004-12-01
COMPLETED
A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight LossNCT00108524 · 2004-07-01
COMPLETED
The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS)NCT01475019 · 2004-01-01
UNKNOWN
Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese AdultsNCT02706067 · 2002-07-01
COMPLETED
Effectiveness of Brief Counseling for Weight ManagementNCT00212199 · 2002-01-01
COMPLETED
Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related DiseasesNCT00001723 · 1998-05-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.